Regenerative Medicine Advanced Therapy (RMAT) designation follows Phase Ib 36-month data Study demonstrated favorable safety profile and continued positive trends in assessed clinical outcome measures ...
Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...
PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results for the fourth quarter ...
Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving ...
In this digital era, Vamsi Upputuri, a leading expert in regulatory automation, explores cutting-edge advancements in ...
The trial will explore the effects of higher doses of ACD856, building on the drug’s established safety profile.
Imagion Biosystems has initiated manufacturing of its MagSense imaging agent for its phase II clinical study on HER2+ breast cancer, an essential requirement for filing an Investigational New Drug ...
Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback